237 related articles for article (PubMed ID: 12697685)
1. Characterization of neuropeptide Y (NPY) Y5 receptor-mediated obesity in mice: chronic intracerebroventricular infusion of D-Trp(34)NPY.
Mashiko S; Ishihara A; Iwaasa H; Sano H; Oda Z; Ito J; Yumoto M; Okawa M; Suzuki J; Fukuroda T; Jitsuoka M; Morin NR; MacNeil DJ; Van der Ploeg LH; Ihara M; Fukami T; Kanatani A
Endocrinology; 2003 May; 144(5):1793-801. PubMed ID: 12697685
[TBL] [Abstract][Full Text] [Related]
2. Energy metabolic profile of mice after chronic activation of central NPY Y1, Y2, or Y5 receptors.
Henry M; Ghibaudi L; Gao J; Hwa JJ
Obes Res; 2005 Jan; 13(1):36-47. PubMed ID: 15761161
[TBL] [Abstract][Full Text] [Related]
3. Evidence that the inhibition of luteinizing hormone secretion exerted by central administration of neuropeptide Y (NPY) in the rat is predominantly mediated by the NPY-Y5 receptor subtype.
Raposinho PD; Broqua P; Pierroz DD; Hayward A; Dumont Y; Quirion R; Junien JL; Aubert ML
Endocrinology; 1999 Sep; 140(9):4046-55. PubMed ID: 10465275
[TBL] [Abstract][Full Text] [Related]
4. Neuropeptide Y1 and Y5 receptors mediate the effects of neuropeptide Y on the hypothalamic-pituitary-thyroid axis.
Fekete C; Sarkar S; Rand WM; Harney JW; Emerson CH; Bianco AC; Beck-Sickinger A; Lechan RM
Endocrinology; 2002 Dec; 143(12):4513-9. PubMed ID: 12446577
[TBL] [Abstract][Full Text] [Related]
5. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice.
Kanatani A; Mashiko S; Murai N; Sugimoto N; Ito J; Fukuroda T; Fukami T; Morin N; MacNeil DJ; Van der Ploeg LH; Saga Y; Nishimura S; Ihara M
Endocrinology; 2000 Mar; 141(3):1011-6. PubMed ID: 10698177
[TBL] [Abstract][Full Text] [Related]
6. Combined deletion of Y1, Y2, and Y4 receptors prevents hypothalamic neuropeptide Y overexpression-induced hyperinsulinemia despite persistence of hyperphagia and obesity.
Lin EJ; Sainsbury A; Lee NJ; Boey D; Couzens M; Enriquez R; Slack K; Bland R; During MJ; Herzog H
Endocrinology; 2006 Nov; 147(11):5094-101. PubMed ID: 16873543
[TBL] [Abstract][Full Text] [Related]
7. An insurmountable NPY Y5 receptor antagonist exhibits superior anti-obesity effects in high-fat diet-induced obese mice.
Fukasaka Y; Nambu H; Tanioka H; Obata A; Tonomura M; Okuno T; Yukioka H
Neuropeptides; 2018 Aug; 70():55-63. PubMed ID: 29801968
[TBL] [Abstract][Full Text] [Related]
8. Chronic neuropeptide Y infusion into the lateral ventricle induces sustained feeding and obesity in mice lacking either Npy1r or Npy5r expression.
Raposinho PD; Pedrazzini T; White RB; Palmiter RD; Aubert ML
Endocrinology; 2004 Jan; 145(1):304-10. PubMed ID: 14525913
[TBL] [Abstract][Full Text] [Related]
9. Activation of the NPY Y5 receptor regulates both feeding and energy expenditure.
Hwa JJ; Witten MB; Williams P; Ghibaudi L; Gao J; Salisbury BG; Mullins D; Hamud F; Strader CD; Parker EM
Am J Physiol; 1999 Nov; 277(5):R1428-34. PubMed ID: 10564216
[TBL] [Abstract][Full Text] [Related]
10. Food intake in free-feeding and energy-deprived lean rats is mediated by the neuropeptide Y5 receptor.
Criscione L; Rigollier P; Batzl-Hartmann C; Rüeger H; Stricker-Krongrad A; Wyss P; Brunner L; Whitebread S; Yamaguchi Y; Gerald C; Heurich RO; Walker MW; Chiesi M; Schilling W; Hofbauer KG; Levens N
J Clin Invest; 1998 Dec; 102(12):2136-45. PubMed ID: 9854049
[TBL] [Abstract][Full Text] [Related]
11. Selective activation of central NPY Y1 vs. Y5 receptor elicits hyperinsulinemia via distinct mechanisms.
Gao J; Ghibaudi L; Hwa JJ
Am J Physiol Endocrinol Metab; 2004 Oct; 287(4):E706-11. PubMed ID: 15187000
[TBL] [Abstract][Full Text] [Related]
12. Responsiveness of obese Zucker rats to [D-Trp34]-NPY supports the targeting of Y5 receptor for obesity treatment.
Beck B; Richy S; Stricker-Krongrad A
Nutr Neurosci; 2007; 10(5-6):211-4. PubMed ID: 18284029
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system neuropeptide Y signaling via the Y1 receptor partially dissociates feeding behavior from lipoprotein metabolism in lean rats.
Rojas JM; Stafford JM; Saadat S; Printz RL; Beck-Sickinger AG; Niswender KD
Am J Physiol Endocrinol Metab; 2012 Dec; 303(12):E1479-88. PubMed ID: 23074243
[TBL] [Abstract][Full Text] [Related]
14. A pair-feeding study reveals that a Y5 antagonist causes weight loss in diet-induced obese mice by modulating food intake and energy expenditure.
Mashiko S; Ishihara A; Iwaasa H; Sano H; Ito J; Gomori A; Oda Z; Moriya R; Matsushita H; Jitsuoka M; Okamoto O; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A
Mol Pharmacol; 2007 Feb; 71(2):602-8. PubMed ID: 17105869
[TBL] [Abstract][Full Text] [Related]
15. L-152,804: orally active and selective neuropeptide Y Y5 receptor antagonist.
Kanatani A; Ishihara A; Iwaasa H; Nakamura K; Okamoto O; Hidaka M; Ito J; Fukuroda T; MacNeil DJ; Van der Ploeg LH; Ishii Y; Okabe T; Fukami T; Ihara M
Biochem Biophys Res Commun; 2000 May; 272(1):169-73. PubMed ID: 10872822
[TBL] [Abstract][Full Text] [Related]
16. Chronic administration of neuropeptide Y into the lateral ventricle of C57BL/6J male mice produces an obesity syndrome including hyperphagia, hyperleptinemia, insulin resistance, and hypogonadism.
Raposinho PD; Pierroz DD; Broqua P; White RB; Pedrazzini T; Aubert ML
Mol Cell Endocrinol; 2001 Dec; 185(1-2):195-204. PubMed ID: 11738809
[TBL] [Abstract][Full Text] [Related]
17. Selective antagonism of the NPY Y5 receptor does not have a major effect on feeding in rats.
Turnbull AV; Ellershaw L; Masters DJ; Birtles S; Boyer S; Carroll D; Clarkson P; Loxham SJ; McAulay P; Teague JL; Foote KM; Pease JE; Block MH
Diabetes; 2002 Aug; 51(8):2441-9. PubMed ID: 12145156
[TBL] [Abstract][Full Text] [Related]
18. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.
Moriya R; Mashiko S; Ishihara A; Takahashi T; Murai T; Ito J; Mitobe Y; Oda Z; Iwaasa H; Takehiro F; Kanatani A
Peptides; 2009 Jul; 30(7):1318-22. PubMed ID: 19394383
[TBL] [Abstract][Full Text] [Related]
19. Differential roles for neuropeptide Y Y1 and Y5 receptors in anxiety and sedation.
Sørensen G; Lindberg C; Wörtwein G; Bolwig TG; Woldbye DP
J Neurosci Res; 2004 Sep; 77(5):723-9. PubMed ID: 15352219
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Over-Expression of Neuropeptide Y in Hypothalamic Paraventricular Nucleus Contributes to Adipose Tissue Insulin Resistance Partly via the Y5 Receptor.
Long M; Zhou J; Li D; Zheng L; Xu Z; Zhou S
PLoS One; 2015; 10(5):e0126714. PubMed ID: 25993471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
